Marietta Eye Clinic | Marietta, GA

Research site

(Unclaimed)

Location

895 Canton Road, Building 200, Marietta, Georgia, United States of America

Site insights

Top conditions

Top treatments

JNJ-81201887

Sirolimus

RG7774

THR-149

Fluocinolone Acetonide

Aflibercept

DE-109

Triamcinolone Acetonide

ONL1204

Abicipar Pegol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 22 total trials

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling

Macular Degeneration

Geographic Atrophy

Other: Sham Procedure

Drug: JNJ-81201887

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting

Macular Edema Secondary to Retinal Vein Occlusion

Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Drug: Sham

Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens (EUCALYPTUS)

This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will...

Enrolling

Myopia

Myopia Progression

Device: Single vision, impact-resistant spectacle lenses; Test Arm

Device: Single vision, impact-resistant spectacle lenses; Control Arm

Fenofibrate for Prevention of DR Worsening (Protocol AF)

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling

Diabetic Retinopathy

Other: Placebo

Drug: Fenofibrate

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uve...

Active, not recruiting

Uveitis, Posterior

Drug: Fluocinolone Acetonide Intravitreal Implant 0.18 mg

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial (VOYAGE)

The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, am...

Active, not recruiting

Diabetic Retinopathy

Drug: Aflibercept Injection